Scaricare la presentazione
La presentazione è in caricamento. Aspetta per favore
1
Volume 68, Issue 1, Pages 147-153 (July 2015)
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study Orazio Caffo, Ugo De Giorgi, Lucia Fratino, Daniele Alesini, Vittorina Zagonel, Gaetano Facchini, Donatello Gasparro, Cinzia Ortega, Marcello Tucci, Francesco Verderame, Enrico Campadelli, Giovanni Lo Re, Giuseppe Procopio, Roberto Sabbatini, Maddalena Donini, Franco Morelli, Donata Sartori, Paolo Zucali, Francesco Carrozza, Alessandro D’Angelo, Giovanni Vicario, Francesco Massari, Daniele Santini, Teodoro Sava, Caterina Messina, Giuseppe Fornarini, Leonardo La Torre, Riccardo Ricotta, Michele Aieta, Claudia Mucciarini, Fable Zustovich, Sveva Macrini, Salvatore Luca Burgio, Sandra Santarossa, Carmine D’Aniello, Umberto Basso, Sara Tarasconi, Enrico Cortesi, Consuelo Buttigliero, Fiorella Ruatta, Antonello Veccia, Vincenza Conteduca, Francesca Maines, Enzo Galligioni European Urology Volume 68, Issue 1, Pages (July 2015) DOI: /j.eururo Copyright © 2014 European Association of Urology Terms and Conditions
2
Fig. 1 New agent–based treatments after docetaxel failure.
AA=abiraterone acetate; CAB=cabazitaxel; ENZ=enzalutamide. European Urology , DOI: ( /j.eururo ) Copyright © 2014 European Association of Urology Terms and Conditions
3
Fig. 2 Overall survival from start of third-line treatment, by prognostic group (median values: group 1: 5 mo; group 2: 9 mo; group 3: 20 mo; log-rank p<0.001). European Urology , DOI: ( /j.eururo ) Copyright © 2014 European Association of Urology Terms and Conditions
4
Fig. 3 Overall survival from start of docetaxel by prognostic group (median values: group 1: 24 mo; group 2: 32 mo; group 3: 80 mo; log-rank p<0.001). European Urology , DOI: ( /j.eururo ) Copyright © 2014 European Association of Urology Terms and Conditions
Presentazioni simili
